Difference between revisions of "Succinate"

From Bioblast
Jump to: navigation, search
 
Line 2: Line 2:
 
|abbr=S
 
|abbr=S
 
|description=[[File:Succinic_acid.jpg|left|100px|Succinic acid]]
 
|description=[[File:Succinic_acid.jpg|left|100px|Succinic acid]]
'''Succinic acid''', C<sub>4</sub>H<sub>6</sub>O<sub>4</sub>, (butanedioic acid) is a dicarboxylic acid which occurs under physiological conditions as the anion '''succinate<sup>2-</sup>, S''', with ''p''K<sub>a1</sub> = 4.2 and ''p''K<sub>a2</sub> = 5.6. Succinate is formed in the [[TCA cycle]], and is a substrate of [[Complex II |CII]], reacting to [[fumarate]] and feeding electrons into the [[Q-junction]]. Succinate (CII-linked) and NADH (CI-linked) provide convergent electron entries into the Q-junction. Succinate is transported across the inner mt-membrane by the [[dicarboxylate carrier]]. The plasma membrane of many cell types is impermeable for succinate (but see [[Zhunussova 2015 Am J Cancer Res]] for an exception). Incubation of mt-preparations by succinate alone may lead to accumulation of [[oxaloacetate]], which is a potent inhibitor of Complex II (compare [[Succinate and rotenone]]). High activities of mt[[Malic enzyme]] (mtME) prevent accumulation of oxaloacetate.
+
'''Succinic acid''', C<sub>4</sub>H<sub>6</sub>O<sub>4</sub>, (butanedioic acid) is a dicarboxylic acid which occurs under physiological conditions as the anion '''succinate<sup>2-</sup>, S''', with ''p''K<sub>a1</sub> = 4.2 and ''p''K<sub>a2</sub> = 5.6. Succinate is formed in the [[TCA cycle]], and is a substrate of [[Complex II |CII]], reacting to [[fumarate]] and feeding electrons into the [[Q-junction]]. Succinate (CII-linked) and NADH (CI-linked) provide convergent electron entries into the Q-junction. Succinate is transported across the inner mt-membrane by the [[dicarboxylate carrier]]. The plasma membrane of many cell types is impermeable for succinate (but see [[Zhunussova 2015 Am J Cancer Res]] for an exception). Incubation of mt-preparations by succinate alone may lead to accumulation of [[oxaloacetate]], which is a potent inhibitor of Complex II (compare [[Succinate and rotenone]]). High activities of mt-[[Malic enzyme]] (mtME) prevent accumulation of oxaloacetate.
|info=[[Gnaiger 2014 MitoPathways]], [[Tretter 2016 Biochim Biophys Acta]]
+
|info=[[Gnaiger 2019 MitoPathways]], [[Tretter 2016 Biochim Biophys Acta]]
 
}}
 
}}
 
{{MitoPedia topics
 
{{MitoPedia topics

Latest revision as of 09:01, 12 August 2019

Bioblasts - Richard Altmann and MiPArt by Odra Noel
MitoPedia         Terms and abbreviations         Concepts and methods         Oroboros O2k         MiP and biochemistry         Preprints and history



MitoPedia

Succinate

Description

Succinic acid

Succinic acid, C4H6O4, (butanedioic acid) is a dicarboxylic acid which occurs under physiological conditions as the anion succinate2-, S, with pKa1 = 4.2 and pKa2 = 5.6. Succinate is formed in the TCA cycle, and is a substrate of CII, reacting to fumarate and feeding electrons into the Q-junction. Succinate (CII-linked) and NADH (CI-linked) provide convergent electron entries into the Q-junction. Succinate is transported across the inner mt-membrane by the dicarboxylate carrier. The plasma membrane of many cell types is impermeable for succinate (but see Zhunussova 2015 Am J Cancer Res for an exception). Incubation of mt-preparations by succinate alone may lead to accumulation of oxaloacetate, which is a potent inhibitor of Complex II (compare Succinate and rotenone). High activities of mt-Malic enzyme (mtME) prevent accumulation of oxaloacetate.

Abbreviation: S

Reference: Gnaiger 2019 MitoPathways, Tretter 2016 Biochim Biophys Acta


MitoPedia topics: Substrate and metabolite 



Succinate, S. From Gnaiger 2014 MitoPathways.

Application in HRR

S: Succinate (Succinate disodium salt, hexahydrate, C4H404Na2 * (H2O)6)

Sigma S 2378, 100 g, store at RT; FW = 270.1
Preparation of 1 M stock solution:
  1. Weight 1.3505 g of succinate and dissolve in 3 mL H2O;
  2. Check pH and adjust to 7.0 if necessary with 1 M HCl (usually the pH is 7 without any adjustment);
  3. Transfer to 5 mL volumetric glass flask and adjust the final volume to 5 mL;
  4. Divide into 0.5 mL portions;
  5. Store frozen at -20 °C.


O2k manual titrations MiPNet09.12 O2k-Titrations
  • In the absence of CI-linked substrates, add the CI-inhibitor rotenone before addition of succinate, to avoid accumulation of oxaloacetate with subsequent inhibition of succinate dehydrogenase. See: Succinate and rotenone.
  • When keeping the succinate stock solution on ice, check for complete solubilization of succinate and warm the stock solution in your hands if necessary.
  • Titration volume: 20 µL using a 50 µL syringe (2 mL O2k-chamber).
  • Final concentration: 10 mM.

SUITbrowser question: Succinate pathway

The SUITbrowser can be used to find the best SUIT protocols to analyze the succinate pathway, among other research questions.